NCT01970410View on ClinicalTrials.gov

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2021

Study Completion Date

February 14, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

teriflunomide

14 mg oral teriflunomide daily

Trial Locations (3)

12110

Multiple Sclerosis Center of Northeastern New York, Latham

85018

Phoenix Neurological Associates, Ltd, Phoenix

97225

Providence Multiple Sclerosis Center, Portland

All Listed Sponsors
collaborator

Multiple Sclerosis Center of Northeastern New York

OTHER

lead

Providence Health & Services

OTHER

NCT01970410 - MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV | Biotech Hunter | Biotech Hunter